1. Bartlett J, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000;31:347-382.
2.
2. Year 2003 Antibiotic Selection for Community-Acquired Pneumonia (ASCAP) Panel Consensus Report. Community-acquired pneumonia (CAP):evidence-based antibiotic selection and outcomeeffective patient management—year 2003 update. Hosp Med Cons Rep. 2003(March):1-40.
3.
3. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. JAMA. 1995;274:134-141.
4.
4. SchwartzR. The diagnosis and management of sinusitis. Nurse Pract. 1994;19:58-63.
5.
5. Steinman MA, Landefeld CS, GonzalesR. Predictors of broadspectrum antibiotic prescribing for acute respiratory tract infections in adult primary care. JAMA. 2003;289:719-725.
6.
6. Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories. Clin Infect Dis. 2001;32(suppl 1):S39-S46.
7.
7. Schentag JJ, Birmingham MC, Paladino JA, et al. In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is amore important determinant of successful clinical outcome, and a better means of avoiding resistance. Sem Respir Medicine. 1997;12:278-293.
8.
8. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community acquired pneumonia in the era of pneumococcal resistance. A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med. 2000;160:1399-1408.
9.
9. Piccirillo JF, Mager DE, Frisse ME, etal. Impactof first-line vs. second-line antibiotics for the treatment of acute uncomplicated sinusitis. JAMA. 2001;286:1849-1856.
